Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
skin and connective tissue diseases | D017437 |
Brand Name | Status | Last Update |
---|---|---|
verzenio | New Drug Application | 2024-01-03 |
Expiration | Code | ||
---|---|---|---|
ABEMACICLIB, VERZENIO, ELI LILLY AND CO | |||
2024-10-12 | I-877, NPP |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Abemaciclib, Verzenio, Eli Lilly And Co | |||
7855211 | 2029-12-15 | DS, DP | U-1981, U-2132, U-2135, U-2251, U-3241, U-3242, U-3243, U-3265, U-3546 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 28 | 39 | 11 | 3 | 10 | 79 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 5 | 2 | 3 | 1 | — | 10 |
Triple negative breast neoplasms | D064726 | — | — | 1 | 5 | 1 | 1 | 1 | 8 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 19 | 14 | 1 | — | 1 | 30 |
Prostatic neoplasms | D011471 | — | C61 | 4 | 6 | 2 | — | — | 9 |
Non-small-cell lung carcinoma | D002289 | — | — | 6 | 3 | 1 | — | — | 9 |
Male breast neoplasms | D018567 | — | — | 1 | 1 | 3 | — | — | 5 |
Liposarcoma | D008080 | — | — | — | 1 | 1 | — | — | 2 |
Urogenital neoplasms | D014565 | EFO_0003863 | D07 | — | — | 1 | — | — | 1 |
Diarrhea | D003967 | HP_0002014 | R19.7 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Endometrial neoplasms | D016889 | EFO_0004230 | — | 2 | 6 | — | — | — | 7 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | 4 | 4 | — | — | — | 6 |
Castration-resistant prostatic neoplasms | D064129 | — | — | 2 | 3 | — | — | — | 4 |
Glioblastoma | D005909 | EFO_0000515 | — | 2 | 2 | — | — | — | 4 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 4 | 1 | — | — | — | 4 |
Colorectal neoplasms | D015179 | — | — | 4 | 2 | — | — | — | 4 |
Head and neck neoplasms | D006258 | — | — | — | 4 | — | — | — | 4 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | 4 | — | — | — | 4 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 2 | 1 | — | — | — | 3 |
Multiple myeloma | D009101 | — | C90.0 | 2 | 2 | — | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 8 | — | — | — | — | 8 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | — | — | — | — | 2 |
Primary myelofibrosis | D055728 | — | D47.4 | 2 | — | — | — | — | 2 |
Glioma | D005910 | EFO_0000520 | — | 2 | — | — | — | — | 2 |
Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
Hematologic neoplasms | D019337 | — | — | 1 | — | — | — | — | 1 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | — | 1 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | — | — | — | — | 1 |
Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
Drug common name | Abemaciclib |
INN | abemaciclib |
Description | Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.
|
Classification | Small molecule |
Drug class | cyclin dependent kinase inhibitors (formerly-cidib) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1 |
PDB | — |
CAS-ID | 1231929-97-7 |
RxCUI | — |
ChEMBL ID | CHEMBL3301610 |
ChEBI ID | — |
PubChem CID | 46220502 |
DrugBank | DB12001 |
UNII ID | 60UAB198HK (ChemIDplus, GSRS) |